CR6881A - PIRAZOL DERIVATIVES - Google Patents
PIRAZOL DERIVATIVESInfo
- Publication number
- CR6881A CR6881A CR6881A CR6881A CR6881A CR 6881 A CR6881 A CR 6881A CR 6881 A CR6881 A CR 6881A CR 6881 A CR6881 A CR 6881A CR 6881 A CR6881 A CR 6881A
- Authority
- CR
- Costa Rica
- Prior art keywords
- formula
- compounds
- pharmaceutical compositions
- methods
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA INVENCION PROPORCIONA COMPUESTOS DE LA FORMULA 1, DONDE R1, R2, R3 Y R4 SON COMO SE DEFINEN Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. SE INDICAN QUE LOS COMPUESTOS DE LA FORMULA 1 TIENEN ACTIVIDAD PARA INHIBIR LAS CDK5, CDK2 Y GSK-3. PROPORCIONA COMPOSICIONES FARMACEUTICAS Y METODOS QUE COMPRENDEN COMPUESTOS DE LA FORMULA 1 PARA TRATAR Y PREVENIR ENFERMEDADES Y CONDICIONES QUE IMPLICAN CRECIMIENTO CELULAR ANORMAL, TALES COMO EL CANCER Y ENFERMEDADES Y CONDICIONES NEURODEGENERATIVAS Y LAS AFECTADAS POR LA NEUROTRANSMISION DE LA DOPAMINA. TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS Y METODOS QUE COMPRENDEN COMPUESTOS DE LA FORMULA 1 PARA TRATAR LA FERTILIDAD MASCULINA Y LA MOTILIDAD ESPERMATICA, DIABETES MELITUS, DETERIORO A LA TOLERANCIA A LA GLUCOSA, SINDROME METABOLICO O SINDROME X, SINDROME DE POLIQUISTOSIS OVARICA, ADOPOGENESIS Y OBESIDAD, MIOGENESIS Y FRAGILIDAD.THE INVENTION PROVIDES COMPOUNDS OF FORMULA 1, WHERE R1, R2, R3 AND R4 ARE AS DEFINED AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS. IT IS INDICATED THAT THE COMPOUNDS OF FORMULA 1 HAVE ACTIVITY TO INHIBIT THE CDK5, CDK2 AND GSK-3. PROVIDES PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE COMPOUNDS OF FORMULA 1 TO TREAT AND PREVENT DISEASES AND CONDITIONS THAT IMPLY ABNORMAL CELLULAR GROWTH, SUCH AS CANCER AND NEURODEGENERATIVE DISEASES AND AFFECTURING OPENING. ALSO DESCRIBE PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE COMPOUNDS OF FORMULA 1 TO TREAT MALE FERTILITY AND SPERMATIC MOTILITY, MELITUS DIABETES, DETERIORATION TO GLUCOSE TOLERANCE, SYNDROME SYMPOSIS, SYMBOLOSIS, ADOPE SYNTHEOPHYOPHYOPHYOPHYOPHYOPHYOPHYMOPEOLOGY, METHODSOPHYOPHYOPHYMOPEOLOGY, METHODOLOGY, SYNTHEOPHYSIS, ADOPTOLOGY MIOGENESIS AND FRAGILITY.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22941500P | 2000-08-31 | 2000-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR6881A true CR6881A (en) | 2004-03-11 |
Family
ID=22861151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR6881A CR6881A (en) | 2000-08-31 | 2003-01-15 | PIRAZOL DERIVATIVES |
Country Status (38)
Country | Link |
---|---|
EP (1) | EP1313710A1 (en) |
JP (1) | JP2004507526A (en) |
KR (1) | KR20030027093A (en) |
CN (1) | CN1518543A (en) |
AP (1) | AP2001002266A0 (en) |
AR (1) | AR035345A1 (en) |
AU (1) | AU2001280009A1 (en) |
BG (1) | BG107455A (en) |
BR (1) | BR0113574A (en) |
CA (1) | CA2420363A1 (en) |
CR (1) | CR6881A (en) |
CZ (1) | CZ2003468A3 (en) |
DO (1) | DOP2001000243A (en) |
DZ (1) | DZ3398A1 (en) |
EA (1) | EA200300205A1 (en) |
EC (1) | ECSP034480A (en) |
EE (1) | EE200300085A (en) |
GT (1) | GT200100179A (en) |
HN (1) | HN2001000192A (en) |
HR (1) | HRP20030140A2 (en) |
HU (1) | HUP0302669A3 (en) |
IL (1) | IL154016A0 (en) |
IS (1) | IS6687A (en) |
MA (1) | MA26946A1 (en) |
MX (1) | MXPA03001785A (en) |
NO (1) | NO20030958L (en) |
NZ (1) | NZ523656A (en) |
OA (1) | OA12368A (en) |
PA (1) | PA8528101A1 (en) |
PE (1) | PE20020470A1 (en) |
PL (1) | PL360742A1 (en) |
SK (1) | SK2002003A3 (en) |
SV (1) | SV2002000618A (en) |
TN (1) | TNSN01132A1 (en) |
UY (1) | UY26909A1 (en) |
WO (1) | WO2002018346A1 (en) |
YU (1) | YU14703A (en) |
ZA (1) | ZA200301064B (en) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (en) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS P38 KINASE INHIBITORS |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2001290914A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CN102250071A (en) | 2000-12-21 | 2011-11-23 | 沃泰克斯药物股份有限公司 | Pyrazole compounds useful as protein kinase inhibitors |
DK1441724T3 (en) * | 2001-09-27 | 2007-12-03 | Serono Lab | Method for increasing endogenous testosterone levels |
SI1478358T1 (en) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
ES2304531T3 (en) * | 2002-07-17 | 2008-10-16 | Pfizer Italia S.R.L. | HETEROBICICLIC DERIVATIVES OF PIRAZOL AS QUINASA INHIBITORS. |
MXPA05003432A (en) | 2002-10-09 | 2005-07-05 | Pfizer Prod Inc | Pyrazole compounds for treatment of neurodegenerative disorders. |
JP2006504755A (en) * | 2002-10-15 | 2006-02-09 | スミスクライン ビーチャム コーポレーション | Pyridazine compounds as GSK-3 inhibitors |
ES2312968T3 (en) | 2003-02-27 | 2009-03-01 | Smithkline Beecham Corporation | NEW COMPOUNDS. |
PT1626714E (en) | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diaryl ureas for diseases mediated by pdgfr |
US7759382B2 (en) * | 2003-06-05 | 2010-07-20 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
EP1651612B9 (en) * | 2003-07-22 | 2012-09-05 | Astex Therapeutics Limited | 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
EA010485B1 (en) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | N,n-diphenyl urea derivative, pharmaceutical composition (embodiments) thereof, and method for the treatment and prevention of diseases and conditions using it (embodiments) |
BRPI0412820A (en) * | 2003-07-25 | 2006-09-26 | Pfizer | aminopyrazole compounds and use as chk1 inhibitors |
US7671072B2 (en) * | 2003-11-26 | 2010-03-02 | Pfizer Inc. | Aminopyrazole derivatives as GSK-3 inhibitors |
US7244757B2 (en) * | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
WO2005103010A2 (en) * | 2004-04-21 | 2005-11-03 | Astrazeneca Ab | Pyrazole derivatives useful for the treatment of cancer |
WO2005110994A2 (en) | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
US7521560B2 (en) | 2004-06-29 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | 2-substituted quinoline compounds and their uses |
US7491720B2 (en) | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
CN101084214A (en) | 2004-11-17 | 2007-12-05 | 迈卡纳治疗股份有限公司 | Kinase inhibitors |
AR054425A1 (en) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
PL1846394T3 (en) | 2005-02-04 | 2012-04-30 | Astrazeneca Ab | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
JPWO2006085685A1 (en) * | 2005-02-09 | 2008-06-26 | 武田薬品工業株式会社 | Pyrazole compounds |
CA2597813C (en) | 2005-02-16 | 2014-04-22 | Astrazeneca Ab | Chemical compounds |
AU2006248780B2 (en) | 2005-05-16 | 2010-06-03 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
AU2006282896A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
KR101487027B1 (en) | 2005-09-30 | 2015-01-28 | 미카나 테라퓨틱스, 인크. | Substituted pyrazole compounds |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
RU2463302C2 (en) | 2005-10-28 | 2012-10-10 | Астразенека Аб | 4-(3-aminopyrazole)pyrimidine applicable as tyrosine kinase inhibitors for treating malignant growth |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US7528142B2 (en) | 2005-11-03 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20110033438A1 (en) * | 2006-10-18 | 2011-02-10 | Periness Ltd. | Method and pharmacological composition for the diagnosis and treatment of male |
US8642598B2 (en) | 2006-10-21 | 2014-02-04 | Abbvie Inc. | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
JP2010533729A (en) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | Compounds and methods for kinase regulation, and adaptations therefor |
WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
EA019104B1 (en) | 2007-09-21 | 2014-01-30 | Эррей Биофарма Инк. | Glucokinase activators |
WO2009130900A1 (en) * | 2008-04-24 | 2009-10-29 | 日本曹達株式会社 | Oxime derivative, intermediate compound, and plant disease control agent |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
AR078033A1 (en) | 2009-04-03 | 2011-10-12 | Plexxikon Inc | A SOLID DISPERSION, CONTAINING THE COMPOUND {3- [5- (4- (CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDA OF PROPANE-1-SULPHONIC ACID, COMPOSITIONS AND FORMULATIONS THAT INCLUDE SUCH SOLID DISPERSION; METHODS FOR MANUFACTURING SUCH SOLID DISPERSION, FORMS 1 AND 2 |
WO2011041634A1 (en) * | 2009-10-02 | 2011-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazole inhibitors of phosphatidylinositol 3-kinase |
NZ629615A (en) | 2009-11-06 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
JP5998142B2 (en) | 2010-09-27 | 2016-09-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
US9624213B2 (en) | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
AU2014308182B2 (en) | 2013-08-16 | 2018-03-08 | Merck Patent Gmbh | 3-substituted cyclopentylamine derivatives |
CN106580986B (en) * | 2016-11-28 | 2017-09-15 | 王保亮 | A kind of pharmaceutical composition for treating teen bra |
AU2019417833A1 (en) | 2018-12-31 | 2021-06-24 | Biomea Fusion, Inc. | Irreversible inhibitors of menin-MLL interaction |
TW202043205A (en) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Inhibitors of menin-mll interaction |
CN113330000A (en) * | 2019-01-31 | 2021-08-31 | 辉瑞公司 | 3-carbonylamino-5-cyclopentyl-1 FI-pyrrole compound having inhibitory activity against CDK2 |
WO2022135442A1 (en) * | 2020-12-22 | 2022-06-30 | 上海拓界生物医药科技有限公司 | Cdk2 inhibitor and preparation method therefor |
UY39832A (en) | 2021-06-28 | 2023-01-31 | Blueprint Medicines Corp | CDK2 INHIBITORS |
WO2023274397A1 (en) * | 2021-07-01 | 2023-01-05 | 上海拓界生物医药科技有限公司 | Cdk2 inhibitor, preparation method therefor and use thereof |
AU2022331496A1 (en) | 2021-08-20 | 2024-02-29 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
WO2023083201A1 (en) * | 2021-11-09 | 2023-05-19 | 上海拓界生物医药科技有限公司 | Aminopyrazole derivative, and preparation method therefor and use thereof |
WO2023092088A1 (en) * | 2021-11-19 | 2023-05-25 | Blueprint Medicines Corporation | Cdk2 inhibitors and methods of making and using same |
WO2023239629A1 (en) * | 2022-06-06 | 2023-12-14 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade cdk2 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ299156B6 (en) * | 1997-12-22 | 2008-05-07 | Bayer Corporation | Substituted heterocyclic ureas, pharmaceutical compositions in which they are comprised and their use |
KR100579792B1 (en) * | 1998-05-13 | 2006-05-12 | 동화약품공업주식회사 | Novel 2,5-pyridinedicarboxylic acid derivatives |
GB9811427D0 (en) * | 1998-05-29 | 1998-07-22 | Zeneca Ltd | Chemical compounds |
AU6314900A (en) * | 1999-07-26 | 2001-02-13 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
OA12046A (en) * | 1999-08-12 | 2006-05-02 | Pharmacia Italia Spa | 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. |
EA200200411A1 (en) * | 1999-11-30 | 2002-10-31 | Пфайзер Продактс Инк. | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USEFUL AS IMMUNOSUPRESSORS |
BR0110302A (en) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Pyrazole compounds for protein kinase inhibition, pharmaceutically acceptable salt and prodrug, pharmaceutically active metabolite or pharmaceutically acceptable salt of metabolite, pharmaceutical composition, method of treating disease in mammals mediated by protein kinase activity, modulation or inhibition method of the activity of a protein kinase receptor |
-
2001
- 2001-08-24 IL IL15401601A patent/IL154016A0/en unknown
- 2001-08-24 CA CA002420363A patent/CA2420363A1/en not_active Abandoned
- 2001-08-24 CN CNA018147615A patent/CN1518543A/en active Pending
- 2001-08-24 DZ DZ013398A patent/DZ3398A1/en active
- 2001-08-24 SK SK200-2003A patent/SK2002003A3/en not_active Application Discontinuation
- 2001-08-24 PL PL36074201A patent/PL360742A1/en not_active Application Discontinuation
- 2001-08-24 EA EA200300205A patent/EA200300205A1/en unknown
- 2001-08-24 CZ CZ2003468A patent/CZ2003468A3/en unknown
- 2001-08-24 NZ NZ523656A patent/NZ523656A/en unknown
- 2001-08-24 AP APAP/P/2001/002266A patent/AP2001002266A0/en unknown
- 2001-08-24 KR KR10-2003-7002894A patent/KR20030027093A/en not_active Application Discontinuation
- 2001-08-24 HU HU0302669A patent/HUP0302669A3/en unknown
- 2001-08-24 EP EP01958287A patent/EP1313710A1/en not_active Withdrawn
- 2001-08-24 MX MXPA03001785A patent/MXPA03001785A/en not_active Application Discontinuation
- 2001-08-24 YU YU14703A patent/YU14703A/en unknown
- 2001-08-24 JP JP2002523464A patent/JP2004507526A/en active Pending
- 2001-08-24 AU AU2001280009A patent/AU2001280009A1/en not_active Abandoned
- 2001-08-24 OA OA1200300050A patent/OA12368A/en unknown
- 2001-08-24 BR BR0113574-0A patent/BR0113574A/en not_active IP Right Cessation
- 2001-08-24 WO PCT/IB2001/001540 patent/WO2002018346A1/en not_active Application Discontinuation
- 2001-08-24 EE EEP200300085A patent/EE200300085A/en unknown
- 2001-08-27 UY UY26909A patent/UY26909A1/en not_active Application Discontinuation
- 2001-08-28 HN HN2001000192A patent/HN2001000192A/en unknown
- 2001-08-29 PE PE2001000872A patent/PE20020470A1/en not_active Application Discontinuation
- 2001-08-29 DO DO2001000243A patent/DOP2001000243A/en unknown
- 2001-08-29 AR ARP010104115A patent/AR035345A1/en unknown
- 2001-08-30 TN TNTNSN01132A patent/TNSN01132A1/en unknown
- 2001-08-30 GT GT200100179A patent/GT200100179A/en unknown
- 2001-08-30 SV SV2001000618A patent/SV2002000618A/en unknown
- 2001-08-31 PA PA20018528101A patent/PA8528101A1/en unknown
-
2003
- 2003-01-13 BG BG107455A patent/BG107455A/en unknown
- 2003-01-15 CR CR6881A patent/CR6881A/en not_active Application Discontinuation
- 2003-01-16 IS IS6687A patent/IS6687A/en unknown
- 2003-02-07 ZA ZA200301064A patent/ZA200301064B/en unknown
- 2003-02-17 EC EC2003004480A patent/ECSP034480A/en unknown
- 2003-02-21 MA MA27050A patent/MA26946A1/en unknown
- 2003-02-26 HR HR20030140A patent/HRP20030140A2/en not_active Application Discontinuation
- 2003-02-28 NO NO20030958A patent/NO20030958L/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR6881A (en) | PIRAZOL DERIVATIVES | |
GT200100147A (en) | IMIDAZOL DERIVATIVES | |
CR8147A (en) | PIRIDO DERIVATIVES 2, 1A-ISOQUINOLINE, AS DPP-IV INHIBITORS | |
UY26782A1 (en) | DERIVATIVES OF BENZOTIAZOLE | |
GT200100137A (en) | PRO-DRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES. | |
UY26872A1 (en) | DERIVATIVES OF THE 4- PIRIDINE PHENYL | |
DOP2006000169A (en) | BETA-SECRETASE SPIROPIPERIDINE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
PA8442001A1 (en) | DERIVATIVES OF CONDENSED BICYCLIC PIRIMIDINE | |
PA8550101A1 (en) | DERIVATIVES OF BENZAMIDA TIAZOL AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS, AND METHODS FOR USE | |
GT200500375A (en) | PIPERIDINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | |
CY1105301T1 (en) | ARYL-FUSED AZAPOLYCYCLIC COMPOUNDS | |
ECSP10010506A (en) | Derivatives of 1-heterocyclyl-1,5-dihydro-pyrazol [3,4-D] pyrimidino-4-one and its use as PDE9A inhibitors. | |
CR7743A (en) | NEW OXAZOL AND TIAZOL COMPOUNDS AS INHIBITOR OF THE TRANSFORMING GROWTH FACTOR (TGF) | |
UY28135A1 (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
PA8507601A1 (en) | NEW BENZOIMIDAZOL USEFUL DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | |
CO4810375A1 (en) | DERIVATIVES OF 9-AMINO-3-KETO Erythromycin | |
AR020032A1 (en) | DERIVATIVES OF 1,3-METHYL Erythromycin. | |
AR021843A1 (en) | DERIVATIVES OF PROPANOLAMINE SUBSTITUTED WITH HETEROCICLES, PROCEDURE FOR THEIR PREPARATION, AND ITS USE. | |
CY1108584T1 (en) | 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES AS MEDICINES FOR TREATMENT OF STRUCTURE | |
GT200100209A (en) | BRIDGE DERIVATIVES OF PIPERAZINA. | |
AR025046A1 (en) | IL-5 NON-STEROID INHIBITORS, PROCEDURES AND INTERMEDIARIES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITORS | |
PA8592801A1 (en) | BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
UY27034A1 (en) | PIRIMIDINE DERIVATIVES | |
UY28647A1 (en) | AMIDA COMPOUNDS OF ACID 3-AMINO-TIENO (2,3-B) PIRIDIN-2-CARBOXYL REPLACED AND PROCEDURES FOR THEIR PREPARATION AND ITS USES | |
CY1106711T1 (en) | SUBSTITUTED PROPANE-1,3-DIAMINE DERIVATIVES AND THEIR PHARMACEUTICAL USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |